Yeh, Wei Z.
Lea, Rodney
Stankovich, Jim
Sampangi, Sandeep
Laverick, Louise
Van der Walt, Anneke
Jokubaitis, Vilija
Gresle, Melissa
Butzkueven, Helmut
Funding for this research was provided by:
Multiple Sclerosis Australia (19-0735)
Australian Government
Monash University
National Health and Medical Research Council
Article History
Received: 26 May 2023
Accepted: 9 January 2024
First Online: 16 January 2024
Competing interests
: WZY received research support from Multiple Sclerosis Australia, the Australian Government Research Training Program, and Monash University Postgraduate Publications Award during the conduct of the study. AVdW served on advisory boards for Novartis, Biogen, Merck and Roche and NervGen. She received unrestricted research grants from Novartis, Biogen, Merck and Roche. She is currently a co-Principal investigator on a co-sponsored observational study with Roche, evaluating a Roche-developed smartphone app, Floodlight-MS. She has received speaker’s honoraria and travel support from Novartis, Roche, Biogen and Merck. She serves as the Chief operating Officer of the MSBase Foundation (not for profit). Her primary research support is from the National Health and Medical Research Council of Australia and MS Australia. HB has received institutional (Monash University) funding from Biogen, F. Hoffmann-La Roche Ltd, Merck, Alexion, CSL, and Novartis; has carried out contracted research for Novartis, Merck, F. Hoffmann-La Roche Ltd and Biogen; has taken part in speakers’ bureaus for Biogen, Genzyme, UCB, Novartis, F. Hoffmann-La Roche Ltd and Merck; has received personal compensation from Oxford Health Policy Forum for the Brain Health Steering Committee. Other authors reported no relevant disclosures or competing interests.